Bioventus Can Proceed to Clinical Trial of Knee OA Treatment

Bioventus received authorization to proceed under its Investigational New Drug application from FDA, and will proceed to clinical trials evaluating MOTYS™ (PTP-001), a placental tissue particulate, to treat osteoarthritis of the knee.

The study will enroll 20 patients, 40 to 80 years old, testing low and high doses in a single injection of...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us